#nucleotide market

[soumyafwr]

https://carbonfacesocial.org/blogs/80773/Single-Nucleotide-Polymorphism-SNP-Genotyping-Market-Size-Analysis-and-Forecast

Single Nucleotide Polymorphism (SNP) Genotyping Market Size, Analysis and Forecast 2031

[cplconsult-com]

CPL's daily case study on tumblr.... CPL provided a market report on infant formula and animal nutrition supplementation with (mono) nucleotides to improve immune and gut health

[businessadvisory]

Nucleotides Market Outlook, 2023- Forecasts and Opportunities in the Nucleotides Industry by Nitrogenous Base (Pyrimidine, Purine), Application (Pharmaceuticals, Food, and Beverage Additives, Animal Feed Additives, Diagnostic Research), Companies and Countries to 2030

[cbirt]

Pancreatic Cancer and Drug Resistance: Researchers Identify Key Metabolic Regulators

Drug resistance can be countered only by interrupting the adaptive measures taken by the cells to deflect the drug action. Scientists from the School of Pharmacy and Pharmaceutical Sciences, University of Buffalo, performed an extensive study through proteomic analysis that identified key regulators driving the resistance against Gemcitabine, the principal chemotherapeutic against Pancreatic Adenocarcinoma. The study also mentions viable pathways and protein targets onto which therapeutic efforts could be directed to better improve the drug efficacy.

Gemcitabine, first marketed under the brand name Gemzar by Eli Lilly, is an antimetabolite capable of retarding tumor progression and promoting apoptosis by inhibiting DNA synthesis. On its uptake into the tumor cell, the compound is phosphorylated to form gemcitabine monophosphate, which acts as the precursor for its diphosphate and triphosphate forms. The diphosphate interacts and inhibits the ribonucleotide reductase (RNR) complex that maintains the nucleotide levels within the cell, while the triphosphate is a structural analog of deoxycytidine triphosphate(dCTP) and masquerades around as dCTP on its synthesis. In a nucleotide deficient state caused by gemcitabine diphosphate, it competes with dCTP for incorporation into the elongating DNA strand. On achieving this, it causes chain termination, ultimately dismantling the DNA synthesis machinery of the cell.

Continue Reading

[tamanna31]

New Trends of Oligonucleotide Synthesis Market with Industry Analysis by 2024 – 2030

Oligonucleotide Synthesis Industry Overview

The global oligonucleotide synthesis market size was estimated at USD 3.68 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 13.21% from 2024 to 2030. 

The decreasing prices of sequencing have led to increasing demand for custom-made nucleotides for applications across genetic testing, research, forensics applications, and drug development. This has further boosted the demand for oligonucleotide synthesis. The COVID-19 pandemic has affected every market globally and there has been a surge in the demand for efficient treatment against COVID-19.

Gather more insights about the market drivers, restrains and growth of the Oligonucleotide Synthesis Market

Oligonucleotide therapeutics hold immense potential for treating chronic conditions such as cardiovascular diseases, cancers, and retinal disorders. Emerging new applications of oligo sequences in multiple fields of biotechnology are expected to increase market growth. Demand for molecular diagnostics in precision care is an important emerging application field for oligonucleotide synthesis.

The introduction of advanced techniques such as CRISPR and high-throughput sequencing for gene expression analysis has simplified the genetic screening and modification of genomes. Such innovations are observed to influence the demand for oligonucleotide synthesis. Manufacturers invest in technology development to enable the production of long Oligonucleotides with higher precision and better yield to cater to the growing need for custom oligos.

The availability of a regulatory environment that supports the progress of genomics is the key factor contributing to the market growth. Changes in the regulatory policies to provide a well-framed environment for advanced biological research and application in human use are expected to influence demand for oligonucleotide synthesis significantly. Stem cells, regenerative medicine, genetic engineering, and synthetic biology are the prominent fields identified with high potential in healthcare. For instance, the International Society for Stem Cell Research (ISSCR) ethics and public policy committee aims to recognize and resolve issues by conducting open discussions. The committee includes experts in ethics, law, and social policy worldwide.

Browse through Grand View Research's Biotechnology Industry Research Reports.

The global optical genome mapping market size was valued at USD 104.1 million in 2023 and is expected to grow at a CAGR of 26.76% from 2024 to 2030. 

The global therapeutic drug monitoring market size was valued USD 1.80 billion in 2023 and is projected to grow at a CAGR of 3.8% from 2024 to 2030. 

Key Companies & Market Share Insights

Some of the key players operating in the market include Merck KGaA, Thermo Fisher Scientific, Inc., and Agilent Technologies. These players focus on business strategies such as partnerships/collaborations, product launches, and expansion. Twist Bioscience, Biolegio, and LGC Biosearch Technologies are some of the emerging market participants in the oligonucleotide market. These players primarily focus on expansion and partnerships to strengthen their position in the market.

Key Oligonucleotide Synthesis Companies:

·         Thermo Fisher Scientific, Inc.

·         Merck KGaA

·         Danaher Corporation

·         Dharmacon Inc.

·         Agilent Technologies

·         Bio-synthesis

·         Kaneka Eurogentec S.A

·         LGC Biosearch Technologies

·         Biolegio

·         Twist Bioscience

Recent Developments

In October 2023, IDT inaugurated a new therapeutic manufacturing facility to meet the increasing demand in genomic medicine. The new facility is equipped to support the production of therapeutic oligonucleotides, catering to the expanding needs in the field of genomics and personalized medicine.

In September 2023, Danaher Corporation (Integrated DNA Technologies) introduced a range of xGen NGS products tailored for the Ultima Genomics UG 100TM platform. The suite includes adapters, primers, and universal blockers, catering to various applications such as DNA, RNA, & methylation sequencing workflows. This offering is complemented by IDT's proven hybridization capture chemistry, enhancing versatility for researchers.

In July 2023, Analytix introduced two new instruments designed for organic synthesis, including wavePREP, tailored for oligonucleotide synthesis, and Xelsius, a workstation for multireaction synthesis.

In May 2023, GenScript expanded its life sciences facility in Zhenjiang, Jiangsu, China, to offer a rapid, high-purity oligonucleotide and peptide synthesis service tailored for research & development as well as preclinical applications.

In May 2023, Twist Bioscience and CeGaT GmbH launched the Twist Alliance CeGaT RNA Fusion Panel. This collaborative effort aims to provide a specialized tool for oncology research, facilitating the detection of RNA fusions and enabling transcript variant analysis. RNA fusions, a result of chromosomal arrangements often seen in cancers, can now be efficiently studied using this newly introduced panel.

In February 2023, Fluor Corp. and Agilent Technologies, Inc. collaborated to enhance its oligonucleotide therapeutics manufacturing facility in Frederick, Colorado. Under this collaboration, Fluor is expected to support the project's engineering and procurement. The total value of the project is evaluated at USD 725 million.

Order a free sample PDF of the Oligonucleotide Synthesis Market Intelligence Study, published by Grand View Research.

[giresearchstory]

Umami Flavors Market Size, volume, Revenue, Trends Analysis Report 2024-2030

On 2024-9-14 Global Info Research released【Global Umami Flavors Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030】. This report includes an overview of the development of the Umami Flavors industry chain, the market status of Consumer Electronics (Nickel-Zinc Ferrite Core, Mn-Zn Ferrite Core), Household Appliances (Nickel-Zinc Ferrite Core, Mn-Zn Ferrite Core), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Umami Flavors. Umami Flavors refer to one of the five basic tastes, alongside sweet, sour, bitter, and salty. Umami is a Japanese word meaning "pleasant savory taste" and is characterized by a rich, savory flavor often associated with foods high in glutamates and nucleotides. Common sources of umami include foods like tomatoes, soy sauce, mushrooms, aged cheeses, and meats.

Umami enhances the depth and complexity of flavor in dishes and is crucial for creating a well-rounded taste experience.

According to our (Global Info Research) latest study, the global Umami Flavors market size was valued at US$ 1801 million in 2023 and is forecast to a readjusted size of USD 3036 million by 2030 with a CAGR of 7.5% during review period. This report is a detailed and comprehensive analysis for global Umami Flavors market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2024, are provided.

Market segment by Type： Natural Source、Synthetic Source Market segment by Application：Food and Beverage、Foodservice、Household/Retail Major players covered： Givaudan、International Flavors and Fragrances, Inc. (IFF)、Firmenich SA、Symrise、MANE、Takasago International Corporation、Sensient Technologies Corporation、Huabao International Holdings Limited、Cargill, Incorporated、ADM

Market segment by region, regional analysis covers: North America (United States, Canada and Mexico), Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe), Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia),South America (Brazil, Argentina, Colombia, and Rest of South America),Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa). The content of the study subjects, includes a total of 15 chapters: Chapter 1, to describe Umami Flavors product scope, market overview, market estimation caveats and base year. Chapter 2, to profile the top manufacturers of Umami Flavors, with price, sales, revenue and global market share of Umami Flavors from 2019 to 2024. Chapter 3, the Umami Flavors competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast. Chapter 4, the Umami Flavors breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2019 to 2030. Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2019 to 2030. Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2023.and Umami Flavors market forecast, by regions, type and application, with sales and revenue, from 2025 to 2030. Chapter 12, market dynamics, drivers, restraints, trends and Porters Five Forces analysis. Chapter 13, the key raw materials and key suppliers, and industry chain of Umami Flavors. Chapter 14 and 15, to describe Umami Flavors sales channel, distributors, customers, research findings and conclusion.

Data Sources:

Via authorized organizations:customs statistics, industrial associations, relevant international societies, and academic publications etc.

Via trusted Internet sources.Such as industry news, publications on this industry, annual reports of public companies, Bloomberg Business, Wind Info, Hoovers, Factiva (Dow Jones & Company), Trading Economics, News Network, Statista, Federal Reserve Economic Data, BIS Statistics, ICIS, Companies House Documentsm, investor presentations, SEC filings of companies, etc.

Via interviews. Our interviewees includes manufacturers, related companies, industry experts, distributors, business (sales) staff, directors, CEO, marketing executives, executives from related industries/organizations, customers and raw material suppliers to obtain the latest information on the primary market;

Via data exchange. We have been consulting in this industry for 16 years and have collaborations with the players in this field. Thus, we get access to (part of) their unpublished data, by exchanging with them the data we have.

From our partners.We have information agencies as partners and they are located worldwide, thus we get (or purchase) the latest data from them.

Via our long-term tracking and gathering of data from this industry.We have a database that contains history data regarding the market.

Global Info Research is a company that digs deep into global industry information to support enterprises with market strategies and in-depth market development analysis reports. We provides market information consulting services in the global region to support enterprise strategic planning and official information reporting, and focuses on customized research, management consulting, IPO consulting, industry chain research, database and top industry services. At the same time, Global Info Research is also a report publisher, a customer and an interest-based suppliers, and is trusted by more than 30,000 companies around the world. We will always carry out all aspects of our business with excellent expertise and experience.

[industrynewsupdates]

Oligonucleotide Synthesis Market Analysis And Segment Forecast 2024-2030

The global oligonucleotide synthesis market size was estimated at USD 3.68 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 13.21% from 2024 to 2030. 

The decreasing prices of sequencing have led to increasing demand for custom-made nucleotides for applications across genetic testing, research, forensics applications, and drug development. This has further boosted the demand for oligonucleotide synthesis. The COVID-19 pandemic has affected every market globally and there has been a surge in the demand for efficient treatment against COVID-19.

Gather more insights about the market drivers, restrains and growth of the Oligonucleotide Synthesis Market

Oligonucleotide therapeutics hold immense potential for treating chronic conditions such as cardiovascular diseases, cancers, and retinal disorders. Emerging new applications of oligo sequences in multiple fields of biotechnology are expected to increase market growth. Demand for molecular diagnostics in precision care is an important emerging application field for oligonucleotide synthesis.

The introduction of advanced techniques such as CRISPR and high-throughput sequencing for gene expression analysis has simplified the genetic screening and modification of genomes. Such innovations are observed to influence the demand for oligonucleotide synthesis. Manufacturers invest in technology development to enable the production of long Oligonucleotides with higher precision and better yield to cater to the growing need for custom oligos.

The availability of a regulatory environment that supports the progress of genomics is the key factor contributing to the market growth. Changes in the regulatory policies to provide a well-framed environment for advanced biological research and application in human use are expected to influence demand for oligonucleotide synthesis significantly. Stem cells, regenerative medicine, genetic engineering, and synthetic biology are the prominent fields identified with high potential in healthcare. For instance, the International Society for Stem Cell Research (ISSCR) ethics and public policy committee aims to recognize and resolve issues by conducting open discussions. The committee includes experts in ethics, law, and social policy worldwide.

Oligonucleotide Synthesis Market Segmentation

Grand View Research has segmented the global oligonucleotide synthesis market report based on product & service, application, and region:

Product & Service Outlook (Revenue, USD Million, 2018 - 2030)

• Oligonucleotides

o DNA

o Column-based

o Array-based

o RNA

o By Technology

o Column-based

o Array-based

o By Type

o Short RNA Oligos (<65 nt)

o Long RNA Oligos (>65 nt)

o CRISPR (sgRNA)

• Equipment/Synthesizer

• Reagents

• Services

o DNA

o Custom Oligo Synthesis Services

o 25 nmol

o 50 nmol

o 200 nmol

o 1000 nmol

o 10000 nmol

o Modification Services

o Purification Services

o RNA

o Custom Oligo Synthesis Services

o 25 nmol

o 100 nmol

o 1000 nmol

o 10000 nmol

o Modification Services

o Purification Services

Application Outlook (Revenue, USD Million, 2018 - 2030)

• PCR Primers

o Academic Research Institutes

o Diagnostic Laboratories

o Pharmaceutical - Biotechnology Companies

• PCR Assays & Panels

o Academic Research Institutes

o Diagnostic Laboratories

o Pharmaceutical - Biotechnology Companies

• Sequencing

o Academic Research Institutes

o Diagnostic Laboratories

o Pharmaceutical - Biotechnology Companies

• DNA Microarrays

o Academic Research Institutes

o Diagnostic Laboratories

o Pharmaceutical - Biotechnology Companies

• Fluorescence In Situ Hybridization (FISH)

o Academic Research Institutes

o Diagnostic Laboratories

o Pharmaceutical - Biotechnology Companies

• Antisense Oligonucleotides

o Academic Research Institutes

o Diagnostic Laboratories

o Pharmaceutical - Biotechnology Companies

• Other Applications

Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

o U.S.

o Canada

• Europe

o Germany

o U.K.

o France

o Spain

o Italy

o Denmark

o Sweden

o Norway

• Asia Pacific

o China

o Japan

o India

o South Korea

o Australia

o Thailand

• Latin America

o Brazil

o Mexico

o Argentina

• Middle East and Africa (MEA)

o South Africa

o Saudi Arabia

o UAE

o Kuwait

Browse through Grand View Research's Biotechnology Industry Research Reports.

• The global optical genome mapping market size was valued at USD 104.1 million in 2023 and is expected to grow at a CAGR of 26.76% from 2024 to 2030. 

• The global therapeutic drug monitoring market size was valued USD 1.80 billion in 2023 and is projected to grow at a CAGR of 3.8% from 2024 to 2030. 

Key Companies & Market Share Insights

Some of the key players operating in the market include Merck KGaA, Thermo Fisher Scientific, Inc., and Agilent Technologies. These players focus on business strategies such as partnerships/collaborations, product launches, and expansion. Twist Bioscience, Biolegio, and LGC Biosearch Technologies are some of the emerging market participants in the oligonucleotide market. These players primarily focus on expansion and partnerships to strengthen their position in the market.

Key Oligonucleotide Synthesis Companies:

• Thermo Fisher Scientific, Inc.

• Merck KGaA

• Danaher Corporation

• Dharmacon Inc.

• Agilent Technologies

• Bio-synthesis

• Kaneka Eurogentec S.A

• LGC Biosearch Technologies

• Biolegio

• Twist Bioscience

Recent Developments

• In October 2023, IDT inaugurated a new therapeutic manufacturing facility to meet the increasing demand in genomic medicine. The new facility is equipped to support the production of therapeutic oligonucleotides, catering to the expanding needs in the field of genomics and personalized medicine.

• In September 2023, Danaher Corporation (Integrated DNA Technologies) introduced a range of xGen NGS products tailored for the Ultima Genomics UG 100TM platform. The suite includes adapters, primers, and universal blockers, catering to various applications such as DNA, RNA, & methylation sequencing workflows. This offering is complemented by IDT's proven hybridization capture chemistry, enhancing versatility for researchers.

• In July 2023, Analytix introduced two new instruments designed for organic synthesis, including wavePREP, tailored for oligonucleotide synthesis, and Xelsius, a workstation for multireaction synthesis.

• In May 2023, GenScript expanded its life sciences facility in Zhenjiang, Jiangsu, China, to offer a rapid, high-purity oligonucleotide and peptide synthesis service tailored for research & development as well as preclinical applications.

• In May 2023, Twist Bioscience and CeGaT GmbH launched the Twist Alliance CeGaT RNA Fusion Panel. This collaborative effort aims to provide a specialized tool for oncology research, facilitating the detection of RNA fusions and enabling transcript variant analysis. RNA fusions, a result of chromosomal arrangements often seen in cancers, can now be efficiently studied using this newly introduced panel.

• In February 2023, Fluor Corp. and Agilent Technologies, Inc. collaborated to enhance its oligonucleotide therapeutics manufacturing facility in Frederick, Colorado. Under this collaboration, Fluor is expected to support the project's engineering and procurement. The total value of the project is evaluated at USD 725 million.

Order a free sample PDF of the Oligonucleotide Synthesis Market Intelligence Study, published by Grand View Research.

[soumyafwr]

Single Nucleotide Polymorphism (SNP) Genotyping Market Size, Analysis and Forecast 2031

[trendingreportz]

Clinical Oncology Next Generation Sequencing Market - Forecast(2024 - 2030)

Clinical Oncology Next Generation Sequencing Market Overview

Clinical Oncology Next Generation Sequencing Market size was valued at $1.4 billion in 2020 and projected to grow at a CAGR of 13.6% during the forecast period 2021-2026. Next-generation sequencing is a technique that helps to simultaneously perform multiple reactions from which it is possible to sequence DNA or RNA. Biological sciences have been revolutionized by massively parallel sequencing technologies i.e. next-generation sequencing (NGS). Targeted sequencing and re-sequencing provides advantages such as high throughput and lower cost per sample of the process thereby enhancing its application Companion Diagnostics. It is a method of assessing the nucleotide sequence in a DNA section and is used for oncology research and enables researchers to carry out a wide range of applications and study biological systems with their ultra-high throughput, scalability, and speed at a level never before possible. In addition, sequencing of the next generation helps in the evaluation of several genes in a single assay, thus reducing the need to order numerous tests to evaluate the underlying mutation thereby driving the Clinical Oncology Next Generation Sequencing Market. In tumour science, a high implementation rate in whole-genome sequencing (WGS) has been seen in recent years driving the Clinical Oncology Next Generation Sequencing Market Industry. The emergence of next-generation sequencing clinical applications in precision oncology has accelerated key company’s efforts to create new platforms that can be used for genomic assays. In February 2021, for instance, Congenica partnered with Gabriel Precision Oncology Ltd. to create an automatic software interface for clinical oncology interpretation using biotechnology. In routine clinical practice, this product will promote NGS-based molecular diagnostics of tumours. 

Report Coverage

The report: “Clinical Oncology Next Generation Sequencing Market Forecast (2021-2026)”, by Industry ARC, covers an in-depth analysis of the following segments of the Clinical Oncology Next Generation Sequencing Market.

By Technology Type: Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing Centrifuges.

By Application: Screening - Sporadic Cancer and Inherited Cancer, Companion Diagnostics and Other Diagnostics.

By Workflow: NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis.

By End Use: Hospitals/Clinics, Laboratories and Research Labs.

By Geography: North America (U.S, Canada and Mexico), Europe (Germany, UK, France, Italy, Spain, Russia and Rest of Europe), Asia Pacific (China, Japan India, South Korea, Australia & New Zealand, and Rest of Asia Pacific), South America (Brazil, Argentina and Rest of South America) and RoW (Middle East and Africa).

Request Sample

Key Takeaways

The increasing need for successful treatment of various cancer types and scientific developments in immunology, molecular biology and genetics are likely to contribute to the growth of the Clinical Oncology Next Generation Sequencing industry.

Geographically, North America Clinical Oncology Next Generation Sequencing Market held the largest revenue share of 36% in 2020 owing to an increased emphasis on cancer treatment by government agencies, a rise in healthcare spending and the presence of sufficient resources in the healthcare industry in this region.

The growth of the market is driven by rising research and development activities using NGS technologies, growing NGS applications in clinical diagnosis and discovery applications that demand NGS technology.

Detailed analysis on the Strength, Weakness and Opportunities of the prominent players operating in the market is provided in the Clinical Oncology Next Generation Sequencing Market.

Clinical Oncology Next Generation Sequencing Market Segment Analysis - By Technology Type

Based on Technology Type, Clinical Oncology Next Generation Sequencing Market is segmented into Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing Centrifuges. Targeted Sequencing & Resequencing Centrifuges accounted for the largest revenue market share in 2020 help reduce the expense, time, and volume of data analysed during tumour sample sequencing which is anticipated to favourably impact the segment growth. Targeted sequencing uses deep sequencing within an area of interest to identify recognized and novel variants. Illumina's 523-gene panel contains all the probable genes that have the ability to cause malignant tumours to develop. Medical laboratories have introduced the product to diagnose patients suffering from acute myeloid leukaemia. In addition, the efficacy of targeted panels for the identification of malignant tumors improves their clinical usefulness. In 64% of cancer cases, NGS panels are clinically beneficial, according to a report reported in JCO Precision Oncology, 2020 driving the Clinical Oncology Next Generation Sequencing Industry. Whole Genome Sequencing segment is anticipated to grow with the fastest CAGR of 8.3% in the forecast period 2021-2026 owing to the usefulness of this technology to discern and compare normal tissues from tumour tissues, segment growth. Moreover, whole-genome sequencing of cancer patients helps to identify therapies for existing mutations and also helps to target mutations ahead of time. It also helps analyse the prognosis of cancer and establish a treatment regimen depending on the genes affected aiding to the Clinical Oncology Next Generation Sequencing Market growth.

Inquiry Before Buying

Clinical Oncology Next Generation Sequencing Market Segment Analysis - By Application

Based on Application, Clinical Oncology Next Generation Sequencing Market is segmented into Screening - Sporadic Cancer and Inherited Cancer, Companion Diagnostics and Other Diagnostics. Screening accounted for the largest revenue market share in 2020. The most effective way to identify genetic alterations that can be targeted for clinical benefit in cancer patients is currently considered to be NGS-based testing. This technology enables clinicians to analyse several alterations of genes simultaneously. Moreover, as opposed to other pathology methods, technology needs less tumor tissues. An increase in the number of cancer sequencing projects is also increasing the growth of the segment. For instance, 38 different types of cancer were analysed by the Pan-Cancer Analysis of Whole Genomes (PCAWG) Consortium by sequencing more than 2,600 tumour samples aiding to the market's growth. Companion Diagnostics segment is anticipated to grow with the fastest CAGR of 9.1% during the forecast period 2021-2026. Efforts taken by key market participants to develop advanced computational tools propel the segment growth. For instance, in January 2021, scientists from the MD Anderson Cancer Center created CopyKAT, a new computational tool to distinguish between normal as well as cancer cells in a tumour thus enhancing the Companion Diagnostics segment demand.

Clinical Oncology Next Generation Sequencing Market Segment Analysis - By Geography

Based on Geography, North America Clinical Oncology Next Generation Sequencing Market accounted for the 36% revenue share in 2020. This rise is accounted for by substantial efforts made by regulatory bodies to boost cancer screening detection in the U.S. For instance, the U.S.-initiated Cancer Genome Atlas programme, Next-generation sequencing has been conducted by the National Cancer Institute (NCI) of more than 20,000 primary cancer samples from 33 different cancer types. A consortium of 12 cancer centres, including Johns Hopkins University, Dana-Farber Cancer Institute, and others throughout the United States, is the NCI's Cancer Aim Discovery and Growth Network enhancing the Clinical Oncology Next Generation Sequencing Market. In January 2020, in the United States, the Intelligence Advanced Research Projects Activity provided $23 million to the Broad Institute and Harvard University, and DNA Script. In addition, the emergence of a range of laboratories, academic institutions and hospitals that provide early cancer detection and treatment services based on NGS is owing to the growth of the regional sector. For instance, EasyDNA Canada, a Toronto-based DNA Biotechnology testing company, provides Cancer Predisposition Panel tests that use NGS technology to recognise mutations in a total of 98 genes associated with 25 inherited cancers. The test helps to recognise people who at a later stage of their lives are at a high risk of developing cancer drive the regional growth. Asia-Pacific is predicted to be the fastest-growing region during the forecast period 2021- 2026 owing to the increasing automation in the pre-sequencing protocols in this particular region thereby aiding to regional growth.

Schedule a Call

Clinical Oncology Next Generation Sequencing Market Drivers

Increasing Prevalence of Cancer:

Cancer is the second leading cause of death worldwide, according to the WHO, and was responsible for an estimated 9.6 million fatalities in 2018. Need for cancer therapies is rising with the increasing number of cancer cases and deaths caused by cancer. Thus government of various economies focus on drug development, targeted sequencing for the reduction of cancer cases have also increased. Rising biomedical research using next-generation clinical oncology sequencing is estimated to create a favourable environment in the near future for the growth of the next-generation clinical oncology sequencing industry. With substantial advances in genetic sequencing and biomedical science, much research into monoclonal antibodies is now focused on discovering new development targets and optimizing their effectiveness for clinical practice, demonstrating a significant effect on the need for the Clinical Oncology Next Generation Sequencing Market.

Decreasing Sequencing Costs Are Highly Likely To Lead To Market Growth:

In clinical oncology, research and academic institutions are generally interested in the characteristic features of next-generation targeted sequencing technology. The next-generation sequencing techniques in clinical oncology give a high percentage of reads and cost-effectiveness per read. The arrival of low-cost sequencing platforms on the market has made this possible. This increases the overall growth of the next-generation sequencing market for clinical oncology. Several industry players, such as Roche and Illumina, have launched sequencing techniques that have reduced the cost of next-generation sequencing for clinical oncology. Government support for life science research is also estimated to result in the availability of funding for the undertaking of different next-generation sequencing projects in clinical oncology, as well as for the jobs of the staff needed which further act as a driving factor for the growth of the Clinical Oncology Industry.

Clinical Oncology Next Generation Sequencing Market Challenges

Major Regulatory Concerns & Lack Skilled Professionals:

Regulatory concerns regarding usage of Clinical Oncology Next Generation Sequencing Analysis and growing stringent government policy and regulation towards the quantity of service being used in application is restraining growth of the market. Market restrain is also owing to the difficulty in the management of large data and complications, associated with Big Data management. In addition, some of the ethical issues associated with whole-genome sequencing, coupled with the lack of awareness among people are constraining the growth of the market. In addition, the lack of skilled professionals with the sequencing that could be serious for diagnosis purpose set to restrain the market growth. It gets difficult when in an emergency situation, the queue of patients have to wait for experts in the required field negatively impacting the growth.

Buy Now

Clinical Oncology Next Generation Sequencing Industry Outlook:

Product launches, mergers and acquisitions, joint ventures and geographical expansions are key strategies adopted by players in the Clinical Oncology Next Generation Sequencing Market. Clinical Oncology Next Generation Sequencing Market top 10 companies are Illumina, Inc., Qiagen N.V., Pacific Biosciences of California, Inc., Takara Bio, Inc., Creative Biolabs, Mogene LC, F. Hoffmann-La Roche Ltd, Oxford Nanopore Technologies, Agilent Technologies and Thermo Fisher Scientific Inc.

Acquisitions/Product Launches:

In January 2021, 4baseCare, a start-up in precision oncology, partnered with the Advanced Centre for Cancer Treatment, Study and Education (ACTREC), India, to develop ClinOme, an AI-driven platform for clinical interpretation

In May 2020, Illumina, Inc., has partnered with Burning Rock Biotech Limited, a cancer test provider based in China, to promote the standardisation and development within China of the selection of NGS-based cancer therapy. The company has also signed an agreement to develop and commercialise myChoice tumour testing in China with Myriad Genetics, Inc.

In March 2019, Oxford Nanopore Technologies launched a new paradigm of smaller, on-demand DNA or RNA sequencing tests with the potential to transform a variety of applications where rapid insights are needed at a low cost.

[ps1396262]

DNA Data Storage Market Size, Revenue Analysis, Opportunities, Trends, Product Launch, 2024–2030

The DNA Data Storage Market was valued at USD 357 million in 2023-e and will surpass USD 3,100 million by 2030; growing at a CAGR of 89.3% during 2024 - 2030. one of the most fascinating and promising technologies on the horizon is DNA data storage. Imagine storing the entire contents of the Library of Congress in a space no bigger than a sugar cube.

This is not science fiction; it’s the potential of DNA data storage. As the volume of digital data continues to explode, traditional storage mediums like magnetic tapes and hard drives are struggling to keep up. Enter DNA, the blueprint of life, which offers a revolutionary way to store vast amounts of information in an incredibly compact form.

Get a Sample Report: https://intentmarketresearch.com/request-sample/dna-data-storage-market-3588.html

What is DNA Data Storage?

DNA data storage refers to the process of encoding binary data (the 1s and 0s that make up digital files) into the four-letter nucleotide code of DNA (A, T, C, G). This is done by converting binary data into a sequence of DNA nucleotides, which are then synthesized into actual DNA molecules. These molecules can be read back and decoded into the original binary data, making DNA an incredibly dense and durable medium for storing digital information.

Why DNA?

DNA has several unique properties that make it an attractive option for data storage:

Density: DNA is incredibly dense; a single gram of DNA can theoretically store up to 215 petabytes (215 million gigabytes) of data.

Longevity: Unlike traditional storage mediums that degrade over time, DNA can remain stable for thousands of years under the right conditions, ensuring long-term data preservation.

Sustainability: With the growing environmental concerns surrounding data centers and their energy consumption, DNA offers a sustainable alternative, as it requires no power for storage.

The Growing Market for DNA Data Storage

The potential of DNA data storage is attracting significant interest from various industries, including technology, healthcare, and finance. As the demand for data storage continues to surge, companies are exploring DNA as a long-term solution to meet the world’s growing data needs.

Market Trends

Rising Data Generation: The exponential increase in data generation, driven by the Internet of Things (IoT), big data analytics, and artificial intelligence, is one of the primary drivers of the DNA data storage market.

Investment in Research and Development: Companies and research institutions are investing heavily in R&D to overcome the current challenges of DNA data storage, such as the high cost of DNA synthesis and sequencing. Advances in these areas are crucial for making DNA data storage commercially viable.

Collaborations and Partnerships: There has been a rise in collaborations between tech giants, biotech companies, and academic institutions aimed at accelerating the development and commercialization of DNA data storage technology.

Government Initiatives: Governments worldwide are recognizing the strategic importance of advanced data storage technologies and are supporting research initiatives that focus on DNA data storage.

Challenges to Overcome

Despite its enormous potential, DNA data storage faces several challenges that must be addressed before it can become a mainstream technology:

Cost: Currently, the cost of synthesizing and sequencing DNA is prohibitively high. However, as technology advances, these costs are expected to decrease significantly.

Speed: Writing and reading data in DNA is slower than in traditional storage systems. Improving the speed of data retrieval and encoding is a critical area of research.

Error Rates: DNA synthesis and sequencing processes can introduce errors. Developing more accurate and reliable methods is essential for the technology’s success.

Get an insights of Customization: https://intentmarketresearch.com/ask-for-customization/dna-data-storage-market-3588.html

The Road Ahead

The DNA data storage market is still in its infancy, but its future is bright. As technological barriers are overcome, DNA has the potential to revolutionize the way we think about data storage. In the next decade, we can expect to see significant advancements in this field, with DNA storage emerging as a viable solution for archiving vast amounts of data.

The integration of DNA data storage into mainstream technology will likely occur gradually, starting with applications where long-term data preservation is critical, such as in historical archives, government records, and large-scale data centers. As the technology matures, it could eventually become a standard for data storage, offering an efficient, sustainable, and durable solution for the digital age.

Conclusion

The DNA data storage market represents a fascinating intersection of biology and technology, with the potential to transform the future of information storage. As we continue to generate data at an unprecedented rate, DNA may provide the key to unlocking a new era of data management, one where the limits of current storage technologies are surpassed, and the full potential of our digital world is realized.

[rnoni]

Sanger Sequencing Service Market: Current Trends, Key Players, and Future Prospects

Sanger sequencing, a method pioneered by Frederick Sanger, is used for determining the nucleotide sequence of DNA. It remains a foundational technique in genomics, providing high accuracy in sequencing short DNA fragments. This market encompasses services that offer Sanger sequencing for various applications, including clinical diagnostics, research, and pharmaceutical development.

[tamanna31]

mRNA Synthesis Raw Materials Market Size, Share, Growth, Analysis Forecast to 2030

mRNA Synthesis Raw Materials Industry Overview

The global mRNA synthesis raw materials market size was estimated at USD 1.72 billion in 2023 and is anticipated to grow at a CAGR of 2.85% from 2024 to 2030.

mRNA is synthesized by the process of transcription in the nucleus by using a template made up of a DNA nucleotide sequence. It includes various steps such as initiation, elongation, editing, and termination. mRNA synthesis has a broad range of applications in drug discovery, vaccine development, and the manufacturing of therapeutics. RNA-based vaccines have better immunogenicity, higher efficiency, and require short production time. The key factors driving the market growth include the growing academic and industrial interest in mRNA technology, the advantages of mRNA vaccines, and increasing funding for research.

Gather more insights about the market drivers, restrains and growth of the mRNA Synthesis Raw Materials Market

The COVID-19 pandemic created new opportunities for mRNA technology platforms with the introduction and widespread use of vaccines. Government agencies from several nations, research institutions, and numerous biotech and pharmaceutical companies are focusing on efficient and quick methods for the rapid detection of COVID-19. mRNA vaccines are a safe and efficient method for preventing COVID-19. In addition, the advantages associated with the mRNA-based COVID-19 vaccines have sparked the attention of pharmaceutical businesses in delivering vaccines swiftly across the globe.

The National Institute of Allergy & Infectious Diseases and Moderna, Inc. mutually developed the mRNA-1273 (NIAID) in March 2020. It shows 94.1% efficacy in symptomatic prevention from COVID-19 and in December 2020, received emergency use authorization from the US Food & Drug Administration (US FDA) for widespread immunization of people. As a result, the usage of mRNA vaccines increased exponentially during the COVID-19 pandemic.

Recently, RNA centers have been established at numerous institutions to promote therapeutic uses of RNA, particularly in vitro transcribed (IVT) mRNA. These facilities include the Yale Center for RNA Science and Medicine, the RNA Institute at the University of Albany, the State University of New York, and the RNA Therapeutic Institute at the University of Massachusetts in the United States. Additionally, university spin-off businesses funded by significant venture capital infusions such as Argos Medicines, Factor Bioscience, CureVac, Ethris, BioNTech, Moderna, eTheRNA, and Onkaido have advanced the preclinical and clinical development of mRNA-based therapeutics. Hence, growing academic and industrial interest in mRNA technology is anticipated to increase the need for mRNA synthesis raw materials, thereby boosting market growth.

Furthermore, the simplicity to manufacture the mRNA vaccine is a key reason for the development of these vaccines. For instance, it is essential for DNA to enter the nucleus, and then it can be transcribed into mRNA. However, mRNA does not need to enter the nucleus to function as it initiates protein translation in the cytoplasm. Hence, this process makes the mRNA vaccine more efficient and simple to manufacture. In contrast to viral vectors and DNA, mRNAs do not insert into the genome but express the encoded protein instantaneously. Typical cellular processes can eliminate the mRNA since it doesn’t integrate into the host genome, thus eliminating any chance of infection or insertion mutation. In addition, the In Vitro Transcription (IVT) process readily synthesizes mRNA. The process is relatively inexpensive and can be quickly applied to a variety of therapies. Such advantages of mRNA vaccines are anticipated to drive the market during the study period.

Moreover, several operating players in the market and various research institutes are receiving funding for the development of novel mRNA therapeutics. For instance, in October 2022, the University of Columbia received USD 11.1 million in funding from the government of Canada to advance the mRNA vaccine technology. This funding aims to improve their efficacy, reduce the potential side effects of vaccines, and allow for a smaller vaccine dosage. Similarly, in December 2022, ExPLoRNA Therapeutics received USD 813,578 in funding from the Bill & Melinda Gates Foundation to further develop its mRNA technology. Therefore, rising funding for research is expected to increase the need for mRNA synthesis raw materials and fuel the market growth during the forecast period.

Additionally, the growing prevalence of chronic and infectious diseases is increasing the therapeutic application of mRNA technology. For instance, according to WHO, cancer is one of the leading causes of death worldwide, causing almost one in six deaths, while cardiovascular diseases lead to an estimated 17.9 million deaths each year. In addition, according to WHO, about 10 million people worldwide contracted tuberculosis in 2020 (1.1 million children, 5.6 million men, & 3.3 million women). Hence, scientists in industries and universities worldwide are finding novel and innovative ways to develop therapeutics using mRNA technology to prevent and treat disease. For instance, researchers at Penn Medicine are using the mRNA platform to create vaccines for several conditions such as cancer, treatment for food and environmental allergies, genetic diseases, and heart attack and stroke, among others.

Browse through Grand View Research's Biotechnology Industry Research Reports.

• The global recombinant DNA technology market size was valued at USD 728.9 billion in 2023 and is projected to grow at a CAGR of 5.4% from 2024 to 2030.

• The global DNA diagnostics market size was estimated at USD 10.64 billion in 2023 and is projected to grow at a CAGR of 4.51% from 2024 to 2030.

Key mRNA Synthesis Raw Materials Company Insights

The market players operating in the mRNA synthesis raw materials market are adopting product approval to increase the reach of their products in the market and improve the availability of their products in diverse geographical areas, along with expansion as a strategy to enhance production/research activities. In addition, several market players are acquiring smaller players to strengthen their market position. This strategy enables companies to increase their capabilities, expand their product portfolios, and improve their competencies.

Key mRNA Synthesis Raw Materials Companies:

The following are the leading companies in the mRNA synthesis raw materials market. These companies collectively hold the largest market share and dictate industry trends

F. Hoffmann-La Roche Ltd.

Jena Bioscience GmbH

Merck KGaA

Yeasen Biotechnology (Shanghai) Co., Ltd.

BOC Sciences

Thermo Fisher Scientific, Inc.

Maravai LifeSciences

New England Biolabs

Creative Biogene

HONGENE

Recent Developments

In April 2024, Telesis Bio Inc. announced its refocusing strategy to promote its innovative Gibson SOLA platform, targeting DNA and mRNA drug discovery. The company will also concentrate on enhancing its BioXp platform for mRNA synthesis, leveraging its distinct competitive advantage.

In February 2023, Life Edit Therapeutics Inc. and Moderna Inc. signed a collaboration agreement to discover and develop mRNA gene-editing therapies.

In January 2023, BioNTech and the UK Government signed a Strategic Partnership Agreement to help patients by advancing clinical trials for targeted mRNA immune therapies. To provide targeted cancer therapies to up to 10,000 patients by the end of 2030, through clinical trials or as approved treatments

Order a free sample PDF of the MRNA Synthesis Raw Materials Market Intelligence Study, published by Grand View Research.